Gyre Therapeutics, Inc. GYRE Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| All Other Segments | $0— | —— | —— | —— | $0— | |
| Gyre Pharmaceuticals | $22.52M-39.5% | $37.2M+21.7% | $30.56M+14.2% | $26.77M+21.4% | $22.06M-20.9% | |
| Gyre | $0— | —— | —— | —— | $0— | |
| Revenue (Gross) by Product | ||||||
| Contiva | $849-100.0% | $2.5M+100% | $1.25M-30.0% | $1.78M+637,434% | $279— | |
| Etorel | $672-100.0% | $1.48M-4.2% | $1.54M— | —— | —— | |
| Other Product | $31— | —— | $81K— | —— | $73-100.0% | |
| Square Meter Area For Laboratory Center Under Lease by Geography | ||||||
| Nanjing | 700.0% | 700.0% | 700.0% | 700.0% | 70— | |
| Shanghai | 2240.0% | 2240.0% | 2240.0% | 2240.0% | 224— | |
| Zhengzhou | 1800.0% | 1800.0% | 1800.0% | 1800.0% | 180— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gyre Therapeutics, Inc. break its business down?
- Gyre Therapeutics, Inc. (GYRE) reports revenue by business across 3 parts — All Other Segments, Gyre Pharmaceuticals and Gyre. Each is extracted from the segment footnotes and tracked over time.
- Where does Gyre Therapeutics, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gyre Therapeutics, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
